BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for imp...BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.展开更多
目的分析早期结肠癌使用FOLFOX辅助化疗方案的临床疗效。方法方便选取2020年4月—2022年10月聊城市传染病医院收治的80例早期结肠癌患者为研究对象,依照不同化疗方法分为对照组和观察组,各40例。两组均予以腹腔镜根治术治疗,对照组在术...目的分析早期结肠癌使用FOLFOX辅助化疗方案的临床疗效。方法方便选取2020年4月—2022年10月聊城市传染病医院收治的80例早期结肠癌患者为研究对象,依照不同化疗方法分为对照组和观察组,各40例。两组均予以腹腔镜根治术治疗,对照组在术后采取常规化疗方案,观察组在术后则采取FOLFOX辅助化疗方案,比较两组的疗效、T细胞亚群水平、不良反应发生情况。结果观察组治疗总有效率为92.50%(37/40),高于对照组的75.00%(30/40),差异有统计学意义(χ^(2)=4.500,P<0.05)。观察组治疗后辅助性T淋巴细胞(cluster of differentiation 4^(+),CD4^(+))、辅助性T淋巴细胞(cluster of differentiation 4^(+),CD4^(+))/抑制/杀伤性T淋巴细胞(cluster of differentiation 8^(+),CD8^(+))高于对照组,CD8^(+)低于对照组,差异有统计学意义(P均<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论采用FOLFOX辅助化疗方案治疗早期结肠癌患者,有助于提高临床疗效,改善T细胞亚群,同时其不良反应发生率更低,安全性相对更高。展开更多
文摘BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.
文摘目的分析早期结肠癌使用FOLFOX辅助化疗方案的临床疗效。方法方便选取2020年4月—2022年10月聊城市传染病医院收治的80例早期结肠癌患者为研究对象,依照不同化疗方法分为对照组和观察组,各40例。两组均予以腹腔镜根治术治疗,对照组在术后采取常规化疗方案,观察组在术后则采取FOLFOX辅助化疗方案,比较两组的疗效、T细胞亚群水平、不良反应发生情况。结果观察组治疗总有效率为92.50%(37/40),高于对照组的75.00%(30/40),差异有统计学意义(χ^(2)=4.500,P<0.05)。观察组治疗后辅助性T淋巴细胞(cluster of differentiation 4^(+),CD4^(+))、辅助性T淋巴细胞(cluster of differentiation 4^(+),CD4^(+))/抑制/杀伤性T淋巴细胞(cluster of differentiation 8^(+),CD8^(+))高于对照组,CD8^(+)低于对照组,差异有统计学意义(P均<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论采用FOLFOX辅助化疗方案治疗早期结肠癌患者,有助于提高临床疗效,改善T细胞亚群,同时其不良反应发生率更低,安全性相对更高。
